Incorporating founder virus information in vaccine field trials

DOI10.1111/BIOM.12277MaRDI QIDQ3459936zbMATH OpenOpenAlexWikidataFDO

Authors Dean A. Follmann, Chiung-Yu Huang

Publication date 11 January 2016

Published in Biometrics (Search for Journal in Brave)

Full work available at URL http://europepmc.org/articles/pmc4729213

zbMATH Keywords

competing risksempirical processinfectious diseaseCox regressionmarked processburden of illness

Mathematics Subject Classification ID

General nonlinear regression (62J02) Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation
• Sieve analysis using the number of infecting pathogens
• Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials
• Statistical Methods for Assessing Differential Vaccine Protection Against Human Immunodeficiency Virus Types
• Simultaneous inferences of HIV vaccine effects on viral load, CD4 cell counts, and antiretroviral therapy initiation in phase 3 trials

Cites work

• scientific article; zbMATH DE number 946668 (Why is no real title available?)
• Asymptotic Statistics
• Augmented Designs to Assess Immune Response in Vaccine Trials
• Design and analysis of vaccine studies
• On Profile Likelihood
• Proportional hazards models with continuous marks
• Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization
• Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials
• The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy
• The Analysis of Failure Times in the Presence of Competing Risks

Cited in

(4)

• Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation
• Estimation of vaccine efficacy for variants that emerge after the placebo group is vaccinated
• The mechanistic analysis of founder virus data in challenge models
• Chop-Lump Tests for Vaccine Trials

This page was built for publication: Incorporating founder virus information in vaccine field trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3459936)